Skip to content
Menu

Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.

Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.

Read at benzinga.com